#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Retinoblastoma Non-small cell lung cancer recurrent Metastases to peritoneum Systemic sclerosis pulmonary Immune-mediated myasthenia gravis Immune thrombocytopenia Peripheral primitive neuroectodermal tumour of soft tissue Testicular leiomyosarcoma Solitary fibrous tumour Liposarcoma metastatic Glycogen storage disease type I Chemical burn Restless legs syndrome Gastrointestinal stromal tumour Metabolic disorder More trials…

    Learn about Rare Diseases

    Sarcoma – Basic Information Inclusion body myositis – Basic Information Langerhans cell sarcoma Mantle cell lymphoma stage II – Trials in Disease Glycogen storage disease type II – Diagnostics Rhabdoid tumour Prolymphocytic leukaemia – Treatment Ocular melanoma – Trials in Disease Factor IX deficiency – Trials in Disease Wolfram syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Darbepoetin Alfa ORX750 Alfacalcidol Crovalimab Lurasidone Brexpiprazole Fumarate PRT3789 Aptamer-4Ft Nvl-655 Alx148 Pivmecillinam Hydrochloride Larotrectinib Sulfate Gskvx000000014593 Ck-0045 MALIC ACID Nafarelin Pancreas Powder Selatogrel GSKVX000000034798 Bepranemab More therapies…

    Learn about Your Condition

    Childhood asthma Infertility female Pre-eclampsia Autoimmune hepatitis C3 glomerulopathy EGFR gene mutation Menopause Infection Rabies B-cell lymphoma Meniscus operation Anxiety Stargardt's disease Bronchostenosis Renal cancer stage IV More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Uncategorized

  • Study Comparing Olaparib and Pembrolizumab with Chemotherapy and Pembrolizumab for Patients with Advanced Triple-Negative Breast Cancer

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    Investigated Drugs:
    • Carboplatin
    • Gemcitabine
    • Olaparib
    France Germany Hungary Ireland Poland Spain

  • Study of Olaparib for Patients with Advanced Cancer Having HRRm or HRD Mutations

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Olaparib
    Denmark France Ireland Italy Romania Spain

  • Study on the Safety and Effectiveness of ALLO-501A and ALLO-647 for Adults with Relapsed or Refractory Large B-Cell Lymphoma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Diffuse large B-cell lymphoma recurrent
    • Diffuse large B-cell lymphoma refractory
    Investigated Drugs:
    • Allo-501A
    • Allo-647
    • Famotidine
    Italy Spain

  • Study on ALLO-647 and ALLO-501A for Adults with Relapsed or Refractory Large B-Cell Lymphoma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Diffuse large B-cell lymphoma recurrent
    • Diffuse large B-cell lymphoma refractory
    Investigated Drugs:
    • Allo-501A
    • Allo-647
    • Famotidine
    Austria Belgium Germany

  • Study on Ganaxolone for Patients with Refractory Status Epilepticus

    Not recruiting

    3 1
    Investigated Diseases:
    • Status epilepticus
    Investigated Drugs:
    • Ganaxolone
    Austria Belgium Croatia Czechia Denmark Finland +8

  • Study on the Effects of Leriglitazone for Adult Men with Cerebral Adrenoleukodystrophy

    Not recruiting

    3 1
    Investigated Diseases:
    • Adrenoleukodystrophy
    Investigated Drugs:
    • Leriglitazone
    France Germany Spain
Previous Page
1 … 1,642 1,643 1,644 1,645
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!